Cytochrome P-450 monooxygenase (epoxygenase)-derived arachidonic acid (AA) metabolites, including 11,12-epoxyeicosatrienoic acid (11,12-EET), possess anti-inflammatory and antipyretic properties. Prostaglandin E2 (PGE2), a cyclooxygenase (COX)-derived metabolite of AA, is a well-defined mediator of fever and inflammation. We have tested the hypothesis that 11,12-EET attenuates synthesis of PGE2 in monocytes, which are the cells that are indispensable for induction of fever and initiation of inflammation. Monocytes isolated from freshly collected rat blood were stimulated with lipopolysaccharide (LPS; 100 ng/2 × 105 cells) to induce COX-2 and stimulate generation of PGE2. SKF-525A, an inhibitor of epoxygenases, significantly augmented the lipopolysaccharide-provoked synthesis of PGE2 in cell culture in a concentration-dependent manner. It did not affect, however, elevation of the expression of COX-2 protein in monocytes stimulated with LPS. 11,12-EET also did not affect the induction of COX-2 in monocytes incubated with lipopolysaccharide. However, 11,12-EET suppressed, in a concentration-dependent fashion, the generation of PGE2 in incubates. Preincubation of a murine COX-2 preparation for 0–5 min with three concentrations of 11,12-EET (1, 5, and 10 μM) inhibited the oxygenation of [14C]-labeled AA by the enzyme. The inhibitory effect of 11,12-EET on COX-2 was time-and-concentration-dependent, suggesting a mechanism-based inhibition. Based on these data, we conclude that 11,12-EET suppresses generation of PGE2 in monocytes via modulating the activity of COX-2. These data support the hypothesis that epoxygenasederived AA metabolites constitute a negative feedback on the enhanced synthesis of prostaglandins upon inflammation.
Get full access to this article
View all access options for this article.
References
1.
Capdevila JH, Harris RC, Falck JR. Microsomal cytochrome P450 and eicosanoid metabolism. Cell Mol Life Sci59:780–789, 2002.
2.
Oliw EH. Oxygenation of polyunsaturated fatty acids by cytochrome P450 monooxygenases. Prog Lipid Res33:329–354, 1994.
Burger D, Dayer JM. The role of human T-lymphocyte-monocyte contact in inflammation and tissue destruction. Arthritis Res4:S169–S176, 2002.
5.
Baron JM, Zwadlo-Klarwasser G, Jugert F, Hamann W, Rubben A, Mukhtar H, Merk HF. Cytochrome P450 1B1: A major P450 isoenzyme in human blood monocytes and macrophage subsets. Biochem Pharmacol56:1105–1110, 1998.
6.
Carcillo JA, Parise RA, Adedoyin A, Frye R, Branch RA, Romkes M. CYP2D6 mRNA expression in circulating peripheral blood mononuclear cells correlates with in vivo debrisoquine hydroxylase activity in extensive metabolizers. Res Commun Mol Pathol Pharmacol91:149–159, 1996.
7.
Wong PY, Lai PS, Falck JR. Mechanism of signal transduction of 14 R, 15 (S)-epoxyeicosatrienoic acid (14,15-EET) binding in guinea pig monocytes. Prostagl Lipid Mediat62:321–333, 2000.
8.
Fletcher JR. Eicosanoids: Critical agents in the physiological process and cellular injury. Arch Surg128:1192–1196, 1993.
9.
Vane JR. Towards a better aspirin. Nature367:215–216, 1994.
10.
Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol38:97–120, 1998.
Kozak W, Mayfield KP, Kozak A, Kluger MJ. Proadifen (SKF-525A), an inhibitor of cytochrome P-450, augments LPS-induced fever and exacerbates prostaglandin-E2 levels in the rat. J Thermal Biol25:45–50, 2000.
13.
Rotondo D, Abul HT, Milton AS, Davidson J. Pyrogenic immunomodulators increase the level of prostaglandin E2 in the blood simultaneously with the onset of fever. Eur J Pharmacol154:145–152, 1988.
14.
Blatteis CM, Sehic E. Prostaglandin E2: A putative fever mediator. In: Mackowiak PA, Ed. Fever: Basic Mechanism and Management. New York: Raven-Lippincott, pp117–148, 1997.
15.
Milton AS, Wendlandt S. A possible role for prostaglandin E1 as a modulator for temperature regulation in the central nervous system of the cat. J Physiol207:76P–77P, 1970.
16.
Kozak W, Kluger MJ, Tesfaigzi J, Wachulec M, Kozak A, Dokladny K. Molecular mechanism of fever and antipyresis. Ann NY Acad Sci917:121–134, 2000.
17.
Carroll MA, McGiff JC. A new class of lipid mediators: cytochrome P450 arachidonate metabolites. Thorax55:S13–S16, 2000.
18.
Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res78:415–423, 1996.
19.
Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, Busse R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature401:493–497, 1999.
20.
Keeble J, Al-Swayeh OA, Moore PK. Vasorelaxant effect of nitric oxide releasing steroidal and nonsteroidal anti-inflammatory drugs. Br J Pharmacol133:1023–1028, 2001.
21.
Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK. Anti-inflammatory properties of cytochrome P-450 epoxygenase-derived eicosanoids. Science285:1276–1279, 1999.
22.
Kluger MJ. Fever: Role of pyrogens and cryogens. Physiol Rev71:93–127, 1991.
23.
Evans SS, Bain MD, Wang WC. Fever-range hyperthermia stimulates alpha4beta7 integrin-dependent lymphocyte-endothelial adhesion. Int J Hypertherm16:45–59, 2000.
24.
Wang WC, Goldman LM, Schleider DM, Appenheimer MM, Subjeck JR, Repasky EA, Evans SS. Fever-range hyperthermia enhances L-selectin-dependent adhesion of lymphocytes to vascular endothelium. J Immunol160:961–969, 1998.
25.
Cao C, Matsumura K, Shirakawa N, Maeda M, Jikihara I, Kobayashi S, Watanabe Y. Pyrogenic cytokines injected into the rat cerebral ventricle induce cyclooxygenase-2 in brain endothelial cells and also upregulate their receptors. Eur J Neurosci13:1781–1790, 2001.
26.
Li S, Wang Y, Matsumura K, Ballou LR, Morham SG, Blatteis CM. The febrile response to lipopolysaccharide is blocked in cyclooxygenase-2 −/−, but not in cyclooxygenase-1 −/− mice. Brain Res825:86–94, 1999.
27.
Koll S, Goppelt-Struebe M, Hauser I, Goerig M. Monocytic-endothelial cell interaction: regulation of prostanoids synthesis in human coculture. J Leuk Biol61:679–688, 1997.
28.
Kozak W, Kluger MJ, Kozak A, Wachulec M, Dokladny K. Role of cytochrome P-450 in endogenous antipyresis. Am J Physiol279:R455–R460, 2000.
29.
Nakashima T, Yoshida Y, Miyata S, Kiyohara T. Hypothalamic 11,12-epoxyeicosatrienoic acid attenuates fever induced by central interleukin-1beta in the rat. Neurosci Lett310:141–144, 2001.
30.
Kozak W, Milton AS, Abul H, Davidson J, Rotondo D. Lipopolysaccharide, muramyl dipeptide and polyinosinic: policytidylic acid induce the accumulation of inositol phosphates in blood monocytes and lymphocytes. Cell Signal4:345–365, 1989.
31.
Rowlinson SW, Crews BC, Lanzo CA, Marnett LJ. The binding of arachidonic acid in the cyclooxygenase active site of mouse prostaglandin endoperoxide synthase-2 (COX-2). A putative L-shaped binding conformation utilizing the top channel region. J Biol Chem274:23305–23310, 1999.
32.
Fang X, Moore SA, Stoll LL, Rich G, Kaduce TL, Weintraub NL, Spector AA. 14,15-Epoxyeicosatrienoic acid inhibits prostaglandin E2 production in vascular smooth muscle cells. Am J Physiol.275:H2113–H2121, 1998.
33.
Fitzpatrick FA, Ennis MD, Baze ME, Wynalda MA, McGee JE, Liggett WF. Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. J Biol Chem261:15334–15338, 1986.
34.
Boutaud O, Aronoff DM, Richardson JH, Marnett LJ, Oates JA. Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H(2) synthases. Proc Nat Acad Sci99:7130–7135, 2002.
35.
Aronoff D, Boutaud O, Marnet L, Oates J. Inhibition of prostaglandin H2 synthases by salicylate is dependent on the oxidative state of the enzymes. J Pharmacol Exp Ther304:589–595, 2003.
Ristimaki A, Narko K, Hla T. Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: Evidence for post-transcriptional regulation. Biochem J318:325–331, 1996.
38.
Flower RJ. Background and discovery of lipocortins. Agents Actions17:255–262, 1986.
39.
Sebaldt RJ, Sheller JR, Oates JA, Roberts LJ, FitzGerald GA. Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proc Nat Acad Sci USA87:6974–6978, 1990.
40.
Brown NL, Alvi SA, Elder MG, Bennett PR, Sullivan MH. The regulation of prostaglandin output from term intact fetal membranes by anti-inflammatory cytokines. Immunology99:124–133, 2000.
41.
Minghetti L, Polazzi E, Nicolini A, Levi G. Opposite regulation of prostaglandin E2 synthesis by transforming growth factor-beta1 and interleukin 10 in activated microglial cultures. J Neuroimmunol82:31–39, 1998.
42.
Kiemer AK, Lehner MD, Hartung T, Vollmar AM. Inhibition of cyclooxygenase-2 by natriuretic peptides. Endocrinology143:846–852, 2002.
43.
Tanaka Y, Igimi S, Amano F. Inhibition of prostaglandin synthesis by nitric oxide in RAW 264.7 macrophages. Arch Biochem Biophys392:207–217, 2001.
44.
Tetsuka T, Daphna-Iken D, Miller BW, Guan Z, Baier LD, Morrison AR. Nitric oxide amplifies interleukin-1-induced cyclooxygenase-2 expression in rat mesangial cells. J Clin Invest97:2051–2056, 1996.
45.
Pang L, Hoult JR. Repression of inducible nitric oxide synthase and cyclooxygenase-2 by prostaglandin E2 and other cyclic AMP stimulants in J774 macrophages. Biochem Pharmacol53:493–500, 1997.
46.
Willoughby DA, Moore AR, Colville-Nash PR, Gilroy D. Resolution of inflammation. Int J Immunopharmacol22:1131–1135, 2000.
